Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,783 questions · 10,022 findings · 882 reviews

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Tivozanib vs sorafenib (targeted agent versus targeted agent)

Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).

1 finding from 1 review

Intervention not reported

Number of patients with all vascular events (stroke, MI, non‐fatal cardiac arrest, unstable angina requiring revascularisation, vascular death) at 90 days and at 1 year · patients with TIA or ischaemic stroke

The review found no eligible studies for this question.

1 finding from 1 review

CBT vs treatment

Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders

CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with treatment (low certainty).

1 finding from 1 review

CBT vs WAIT LIST

Acceptability (number of participants lost to post‐treatment assessment) · children and adolescents with anxiety disorders

CBT showed no clear difference in acceptability (number of participants lost to post‐treatment… compared with waitlist (low certainty).

1 finding from 1 review